HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Stings Beehive Botanicals For Web Links That "Fell Through The Cracks"

This article was originally published in The Rose Sheet

Executive Summary

Beehive Botanicals has endured product seizure, a complaint from FDA for making unapproved drug claims and potential damage to its reputation because it did not have a firm handle on all dimensions of its online business

You may also be interested in...



FDA Warns JabaLabs About Drug Claims For Anti-Aging Cosmetics

An FDA warning letter to San Antonio, Texas-based skin-care marketer JabaLabs, LLC signals that the agency is continuing its efforts to crack down on overreaching marketing claims for cosmetic products.

FDA Warns JabaLabs About Drug Claims For Anti-Aging Cosmetics

An FDA warning letter to San Antonio, Texas-based skin-care marketer JabaLabs, LLC signals that the agency is continuing its efforts to crack down on overreaching marketing claims for cosmetic products.

Beehive Botanicals consent decree approved

The U.S. District Court for the Western District of Wisconsin enters a consent decree of condemnation and injunction against Beehive Botanicals, under which the manufacturer agrees to forfeit certain bee-derived materials to the Department of Justice. The Hayward, Wis., company had product seized this year after FDA found its website made drug claims via links to other sites for its products, including creams and shampoos (1"The Rose Sheet" April 12, 2010). The decree, entered by the court May 14, additionally requires Beehive Botanicals to hire a third-party expert to inspect its labeling and certify the corrections to FDA, according to a DoJ release

Related Content

UsernamePublicRestriction

Register

RS016848

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel